Nucleoside analogs and tuberculosis: new weapons against an old enemy

Ferrari, Valentina ORCID: https://orcid.org/0000-0003-1895-8906 and Serpi, Michaela ORCID: https://orcid.org/0000-0002-6162-7910 2015. Nucleoside analogs and tuberculosis: new weapons against an old enemy. Future Medicinal Chemistry 7 (3) , pp. 291-314. 10.4155/fmc.14.166

Preview

PDF - Accepted Post-Print Version Download (876kB) | Preview

Abstract

Purine and pyrimidine nucleoside and nucleotide analogs have been extensively studied as anticancer and antiviral agents. In addition to this, they have recently shown great potential against Mycobacterium Tuberculosis, the causative agent of TB. TB ranks as the tenth most common cause of death in the world. The current treatment for TB infection is limited by side effects and cost of the drugs and most importantly by the development of resistance to the therapy. Therefore the development of novel drugs, capable of overcoming the drawbacks of the existing treatments, has become the focus of many research programs. In parallel to that, a tremendous effort has been made to elucidate the unique metabolism of this pathogen with the aim to identify new possible targets. This review presents the state of the art in nucleoside and nucleotide analogs in the treatment of TB. In particular, we report on the inhibitory activity of this class of compounds, both in enzymatic and whole-cell assays, providing a brief insight to which reported target these novel compounds are hitting.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Future Science Ltd
ISSN:	1756-8919
Date of First Compliant Deposit:	30 March 2016
Last Modified:	06 Nov 2023 21:07
URI:	https://orca.cardiff.ac.uk/id/eprint/77078

Citation Data

Cited 13 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item